Screening methods for enzyme-mediated alcohol oxidation

Superoxide Production under Soft X-ray Irradiation of Liquid Water

Soft X-rays behave like particles with high linear energy transfer, as they deposit a large amount of their energy in the nanometric range, triggered by inner-shell ionization. In water, this can lead to the formation of a doubly ionized water molecule (H₂O²⁺) and the emission of two secondary electrons (photoelectron and Auger electron). Our focus lies on detecting and quantifying the superoxide (HO₂°) production via the direct pathway, i.e., from the reaction between the dissociation product of H₂O²⁺, i.e., the oxygen atom (∼4 fs), and the °OH radicals present in the secondary electron tracks. The HO₂° yield for 1620 eV photons, via this reaction pathway, was found to be 0.005 (±0.0007) μmol/J (formed within the ∼ps range). Experiments were also performed to determine the yield of HO₂° production via another (indirect) pathway, involving solvated electrons. The indirect HO₂° yield, measured experimentally as a function of photon energy (from 1700 to 350 eV), resulted in a steep decrease at around 1280 eV and a minimum close to zero at 800 eV. This behavior in contradiction with the theoretical prediction reveals the complexity hidden in the intratrack reactions.

Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real

INTRODUCTION

Biocatalysis has emerged as a powerful and useful strategy for the synthesis of active pharmaceutical ingredients (APIs). The outstanding developments in molecular biology techniques allow nowadays the screening, large-scale production, and designing of biocatalysts, adapting them to desired reactions. Many enzymes can perform reactions both in aqueous and non-aqueous media, broadening even further the opportunities to integrate them in complex pharmaceutical multi-step syntheses.

AREAS COVERED

This paper showcases several examples of biocatalysis in the pharmaceutical industry, covering examples of different enzymes, such as lipases, oxidoreductases, and transaminases, to deliver active drugs through complex synthetic routes. Examples are critically discussed in terms of reaction conditions, motivation for using an enzyme, and how biocatalysts can be integrated in multi-step syntheses. When possible, biocatalytic routes are benchmarked with chemical reactions.

EXPERT OPINION

The reported enzymatic examples are performed with high substrate loadings (>100 g L^-1) and with excellent selectivity, making them inspiring strategies for present and future industrial applications. The combination of powerful molecular biology techniques with the needs of the pharmaceutical industry can be aligned, creating promising platforms for synthesis under more sustainable conditions.